EU/3/01/071

Table of contents

About

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in January 2017 at the end of the period of market exclusivity.

On 5 December 2001 orphan designation (EU/3/01/071) was granted by the European Commission to Biocodex, France, for stiripentol for the treatment of severe myoclonic epilepsy in infancy.

Stiripentol has been authorised in the EU as Diacomit since 4 January 2007.

Key facts

Active substance
stiripentol
Medicine name
Diacomit
Disease / condition
Treatment of severe myoclonic epilepsy in infancy
Date of first decision
06/12/2001
Outcome
Expired
EU designation number
EU/3/01/071

Sponsor's contact details

Biocodex
7 avenue Gallieni
94257 Gentilly
France
Telephone: +33 1 41 24 30 00
Telefax : +33 1 41 24 30 01
E-mail: webar@biocodex.fr

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating